Nectar Lifesciences Limited vs Sun Pharmaceutical Industries Limited
A side-by-side comparison of Nectar Lifesciences Limited (NECLIFE) and Sun Pharmaceutical Industries Limited (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Sun Pharmaceutical Industries Limited leads NECLIFE vs SUNPHARMA on 9 of 14 metrics (2 undecided). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation22
- Profitability04
- Growth· not comparable—
- Size & financial health13
Valuation
EvenHow expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
SUNPHARMA takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
Three-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
SUNPHARMA takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + ["Company is almost debt free.", "Stock is trading at 0.35 times its book value"]
- − ["Company has a low return on equity of -16.3% over last 3 years.", "Company reported a net loss of ₹293 Cr in its latest financial year."]
- + ["Company has delivered good profit growth of 38.3% CAGR over last 5 years", "Company has been maintaining a healthy dividend payout of 33.4%", "Company is almost debt free."]
- − ["Stock is trading at 5.05 times its book value"]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.